MRI/TRUS fusion biopsy allows urologists to take a biopsy from suspicious areas within the prostate. This approach combines magnetic resonance imaging (MRI) scans with transrectal ultrasound (TRUS) images, enabling precise sampling of areas in the prostate that are suspected to be cancerous.
Why This Test is Important
Traditional prostate biopsy involves randomly sampling 12 sections of the prostate with a needle to detect a tumor. Because this method is random, it can miss significant cancers. Due to ongoing suspicion, multiple biopsies may be needed over several years.
With MRI/TRUS fusion biopsy, suspicious areas can be visualized and biopsied accurately. Studies have shown that MRI/TRUS fusion biopsies help detect tumors that require treatment, reduce the number of repeat biopsies, and aid in earlier diagnosis and treatment.
Who Might Need an MRI/TRUS Fusion Biopsy
- Those with elevated prostate-specific antigen (PSA) levels
- Individuals with abnormal findings on a rectal exam
- Patients with normal results from traditional biopsies but ongoing suspicion of cancer
Procedure
Prostate MRI imaging is performed, and suspicious areas are marked on the images. An ultrasound image is then taken to ensure the marked areas on the MRI are visible on the ultrasound. This allows for direct biopsy from the suspicious area with ultrasound guidance. The procedure does not require hospital stay, and patients can return to their daily activities after a one-day rest.
Advantages
- Detects hidden tumors that might be missed by traditional biopsies.
- Reduces the need for multiple biopsies in patients with previously negative biopsy results.
- Facilitates the monitoring of patients with prostate cancer under active surveillance.
- Enables focal therapy in prostate cancer treatment.